Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies

J Nucl Med. 2018 Aug;59(8):1172-1173. doi: 10.2967/jnumed.118.214379. Epub 2018 Jun 14.

Authors

Thomas Langbein¹, Guillaume Chaussé², Richard P Baum³

Affiliations

¹ Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik, Bad Berka, Germany; and [email protected].
² Division of Nuclear Medicine, Department of Radiology, McGill University, Montreal, Canada.
³ Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik, Bad Berka, Germany; and.

PMID: 29903929
DOI: 10.2967/jnumed.118.214379

No abstract available

MeSH terms

Antigens, Surface / adverse effects*
Antigens, Surface / therapeutic use
Glutamate Carboxypeptidase II / adverse effects*
Glutamate Carboxypeptidase II / therapeutic use
Humans
Iodine Radioisotopes / adverse effects
Iodine Radioisotopes / therapeutic use
Ligands
Male
Middle Aged
Prostatic Neoplasms, Castration-Resistant / radiotherapy
Radiation Injuries / etiology*
Radiation Injuries / prevention & control*
Radiation-Protective Agents / pharmacology
Salivary Glands / drug effects
Salivary Glands / radiation effects*

Substances

Antigens, Surface
Iodine Radioisotopes
Iodine-131
Ligands
Radiation-Protective Agents
FOLH1 protein, human
Glutamate Carboxypeptidase II